Trials / Completed
CompletedNCT00255450
A Crossover Safety Study of Ferumoxytol Versus Placebo
A Double Blind, Placebo Controlled, Crossover Design, Multicenter Study of Intravenous Ferumoxytol Compared With Placebo
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 750 (planned)
- Sponsor
- AMAG Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This crossover safety study will evaluate the safety of a single dose of ferumoxytol compared to placebo in patients with chronic kidney disease.
Detailed description
This is a double-blind, placebo controlled, crossover design study of the safety of ferumoxytol compared to placebo. Patients are randomized to receive either one 510 mg dose of ferumoxytol or the equivalent volume of normal saline followed by the other test article given one week later.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ferumoxytol or placebo |
Timeline
- Start date
- 2005-01-01
- Completion
- 2006-08-01
- First posted
- 2005-11-21
- Last updated
- 2008-11-11
Locations
41 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00255450. Inclusion in this directory is not an endorsement.